Ovo Labs develops therapeutics to improve egg quality and IVF success rates by addressing age-related declines in oocyte quality. Their pipeline targets molecular mechanisms that cause chromosome segregation errors, aiming to enhance fertility outcomes for women undergoing treatment.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
In vitro fertilization (IVF) success rates are significantly impacted by egg quality, with a substantial percentage of cycles failing, particularly in women over 35. Age-related accumulation of chromosome segregation errors during egg maturation is a primary driver of this decline in fertility outcomes.
Solution
Ovo Labs is developing a portfolio of therapeutics designed to enhance egg quality and improve IVF success rates. The company's approach targets the underlying causes of IVF failure, specifically addressing age-related declines in oocyte quality. By focusing on egg rejuvenation, Ovo Labs aims to extend the window of high conception probability for women undergoing fertility treatments. Their pipeline includes three distinct therapeutics currently in preclinical development, with the potential to substantially increase IVF success rates across various age demographics.
Target Audience
The primary target audience includes fertility clinics, reproductive endocrinologists, and individuals undergoing IVF treatment seeking to improve conception outcomes.
Features
- Therapeutics targeting the molecular mechanisms of age-related oocyte quality decline.
- Focus on mitigating chromosome segregation errors during oogenesis.
- Pipeline of three distinct egg rejuvenation compounds in preclinical development.
- Potential to improve IVF success rates by 20-30% for women under 35.
- Potential to improve IVF success rates by 3-5 times for women aged 35-45.